Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
McKesson
Moodys
Dow

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208379


Email this page to a colleague

« Back to Dashboard

NDA 208379 describes ZYPITAMAG, which is a drug marketed by Medicure and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ZYPITAMAG profile page.

The generic ingredient in ZYPITAMAG is pitavastatin magnesium. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pitavastatin magnesium profile page.
Summary for 208379
Tradename:ZYPITAMAG
Applicant:Medicure
Ingredient:pitavastatin magnesium
Patents:1
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 208379
Generic Entry Date for 208379*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208379
Suppliers and Packaging for NDA: 208379
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379 NDA Medicure International Inc 25208-201 25208-201-09 90 TABLET, FILM COATED in 1 BOTTLE (25208-201-09)
ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379 NDA Medicure International Inc 25208-201 25208-201-10 1 BLISTER PACK in 1 CARTON (25208-201-10) > 7 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Jul 14, 2017TE:RLD:Yes
Patent:⤷  Try it FreePatent Expiration:Jan 19, 2031Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:Jul 14, 2017TE:RLD:Yes
Patent:⤷  Try it FreePatent Expiration:Jan 19, 2031Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Jul 14, 2017TE:RLD:Yes
Patent:⤷  Try it FreePatent Expiration:Jan 19, 2031Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Merck
McKesson
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.